IP Library Granted Patent US 8,022,088
Granted Patent B2
US 8,022,088 · App. 11/769,018 · Granted Sep 20, 2011

Substituted bicyclic and tricyclic thrombin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,022,088
App. No.
11/769,018
Granted
Sep 20, 2011
Kind
B2
Abstract

Substituted bicyclic and tricyclic modified himbacine derivative of the formula: or a pharmaceutically acceptable salt or solvate of said compound wherein represents an optional double bond and wherein E n , F n , G n , Z n , J n , X, R 3 , R 9 , R 10 , R 11 , R 32 , R 33 , B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other agents is also claimed.

Claims (20)

1. A compound of Formula IK or Formula IIK

or a pharmaceutically acceptable salt thereof

wherein:

Het is a pyridyl group wherein the pyridyl group is attached to B by a carbon atom ring member, and wherein the pyridyl group is substituted by 1 to 4 moieties, W, wherein each W is independently selected from the group consisting of:

hydrogen, alkyl, aryl or aryl substituted by 1 to 3 substituents independently selected from the group consisting of alkyl, halogen, alkoxy,

—CN, —CF 3 , —OCF 3 or —OH;

R 1 is hydrogen, alkyl, fluroalkyl, difluroralkyl or trifluroralkyl;

R 2 is hydrogen, alkyl, fluroalkyl, difluroralkyl or trifluroralkyl;

R 9 is hydrogen;

R 10 and R 11 are H or alkyl;

R 32 and R 33 are H or alkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 32 and R 33 , which can be the same or different, are each alkyl.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 32 and R 33 are each methyl.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Q is

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein W is phenyl, which is unsubstituted or substituted by a group selected from the group consisting of halogen or —CN.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 9 , R 10 and R 11 are hydrogen.

7. A compound of the formula or a pharmaceutically acceptable salt thereof, which is:

8. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.

9. A compound of claim 1 or a pharmaceutically acceptable salt thereof in purified form.

10. A compound of claim 1 or a pharmaceutically acceptable salt thereof in isolated form.

Assignments (3)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2007
From: CHELLIAH, MARIAPPAN V.; CHACKALAMANNIL, SAMUEL; XIA, YAN
To: SCHERING CORPORATION
Reel/Frame 019574/0761 →